jump to content jump to footer

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing treatment response in melanoma and NSCLC patients receiving immune checkpoint inhibitors.

The results indicate that iRECIST is better suited for capturing atypical treatment responses to immunotherapies, especially in patients experiencing pseudoprogression. iRECIST could thus contribute to a more accurate evaluation of treatment response and improved immunotherapy outcomes.

Read more about the study here.

Research with mint mintLesion Clinical Research Standardized Reading Procedures iRECIST RECIST

Related Resources

Woman watching the Mint Medical and contextflow webinars on lung cancer screening in Germany on Youtube
Webinar series to explore different aspects of lung cancer screening in Germany
Webinar Series: Lung Cancer Screening in Germany - From Evidence to Implementation
Lung cancer remains one of the leading causes of cancer-related mortality worldwide. In Germany, the introduction of a national lung cancer screening…
From PCWG3 to PCWG4: Evolving Standards in Prostate Cancer Clinical Trials
The Prostate Cancer Working Group 4 (PCWG4) updates and extends the recommendations of PCWG3 to reflect a patient-centric approach, the emergence of…
Mint Medical and mediaire strengthen the prostate cancer care pathway with AI-Powered MRI Solutions
Mint Medical, a Snke company, and mediaire announce a collaboration to advance AI‑powered MRI workflows through the interoperability of mint Lesion…